Mineralys Therapeutics (MLYS) Research & Development (2022 - 2026)
Mineralys Therapeutics (MLYS) posted Research & Development of $24.4 million for Q1 2026, little changed sequentially from $24.4 million in Q4 2025, and down 35.68% YoY from $37.9 million in Q1 2025.
Mineralys Therapeutics (MLYS) Research & Development (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Research & Development for 5 years, with the latest figure at $24.4 million in Q1 2026.
- Quarterly Research & Development fell 35.68% year-over-year to $24.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $118.5 million (down 32.56% YoY) and the FY2025 annual result came in at $132.0 million, down 21.69% from the prior year.
- Research & Development steadied at $24.4 million in Q1 2026 per MLYS's latest filing, from $24.4 million in the prior quarter.
- Over five years, Research & Development peaked at $54.0 million in Q3 2024 and troughed at $5.6 million in Q2 2022.
- A 5-year average of $24.8 million and a median of $24.4 million in 2026 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2025: Research & Development surged 271.33% in 2023, then plunged 45.25% in 2025.
- Over 5 years, Research & Development stood at $7.8 million in 2022, then jumped by 202.95% to $23.7 million in 2023, then jumped by 88.17% to $44.6 million in 2024, then slumped by 45.25% to $24.4 million in 2025, then fell by 0.15% to $24.4 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $24.4 million, $24.4 million, and $31.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | 221.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 221.38 Mn |
| Mar 31, 2026 | 24.37 Mn |
| Dec 31, 2025 | 24.40 Mn |
| Sep 30, 2025 | 31.45 Mn |
| Jun 30, 2025 | 38.28 Mn |
| Mar 31, 2025 | 37.88 Mn |
| Dec 31, 2024 | 44.57 Mn |
| Sep 30, 2024 | 53.99 Mn |
| Jun 30, 2024 | 39.27 Mn |
| Mar 31, 2024 | 30.75 Mn |
| Dec 31, 2023 | 23.69 Mn |
| Sep 30, 2023 | 22.50 Mn |
| Jun 30, 2023 | 11.88 Mn |
| Mar 31, 2023 | 12.29 Mn |
| Dec 31, 2022 | 7.82 Mn |
| Sep 30, 2022 | 6.06 Mn |
| Jun 30, 2022 | 5.60 Mn |
| Mar 31, 2022 | 6.78 Mn |